Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137003 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Vignesh Sivaganesh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Saint Joseph's University, 600 S 43rd St, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Hydrolyzable Tannins, Receptor Tyrosine Kinase-like Orphan Receptors, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Philadelphia College of Osteopathic Medicine, Abraham and Edythe Roth Endowed Chair.
Abstract (Originalsprache)
Androgen-receptor-negative, androgen-independent (ARneg-AI) prostate cancer aggressively proliferates and metastasizes, which makes treatment difficult. Hence, it is necessary to continue exploring cancer-associated markers, such as oncofetal Receptor Tyrosine Kinase like Orphan Receptor 1 (ROR1), which may serve as a form of targeted prostate cancer therapy. In this study, we identify that Penta-O-galloyl-β-D-glucose (PGG), a plant-derived gallotannin small molecule inhibitor, modulates ROR1-mediated oncogenic signaling and mitigates prostate cancer phenotypes. Results indicate that ROR1 protein levels were elevated in the highly aggressive ARneg-AI PC3 cancer cell line. PGG was selectively cytotoxic to PC3 cells and induced apoptosis of PC3 (IC50 of 31.64 µM) in comparison to normal prostate epithelial RWPE-1 cells (IC50 of 74.55 µM). PGG was found to suppress ROR1 and downstream oncogenic pathways in PC3 cells. These molecular phenomena were corroborated by reduced migration, invasion, and cell cycle progression of PC3 cells. PGG minimally and moderately affected RWPE-1 and ARneg-AI DU145, respectively, which may be due to these cells having lower levels of ROR1 expression in comparison to PC3 cells. Additionally, PGG acted synergistically with the standard chemotherapeutic agent docetaxel to lower the IC50 of both compounds about five-fold (combination index = 0.402) in PC3 cells. These results suggest that ROR1 is a key oncogenic driver and a promising target in aggressive prostate cancers that lack a targetable androgen receptor. Furthermore, PGG may be a selective and potent anti-cancer agent capable of treating ROR1-expressing prostate cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Saint Joseph's University, 600 S 43rd St, Philadelphia, PA 19104, USA.
- Department of Biomedical Sciences, Philadelphia College of Osteopathic Medicine, 4170 City Ave, Philadelphia, PA 19131, USA.
ORCID-Profile: Vignesh Sivaganesh, Tram M Ta, Bela Peethambaran
Förderung
- Philadelphia College of Osteopathic Medicine
- Abraham and Edythe Roth Endowed Chair
Zitieren
APA
Sivaganesh, V., Ta, T. M., & Peethambaran, B. (2024). Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137003
Vancouver
Sivaganesh V, Ta TM, Peethambaran B. Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137003
BibTeX
@article{Sivaganesh2024,
author = {Sivaganesh, Vignesh and Ta, Tram M and Peethambaran, Bela},
title = {Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137003}
}
EUVIMED